Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to each employee's continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 hours ago
- Globe and Mail
1 Stock That Turned $1,000 Into More Than $1 Million
Investors understand that when you extend your time horizon into decades with high-quality businesses, the power of compound growth can work wonders. This is why it's so beneficial to be a long-term owner of companies, allowing their improving fundamentals to positively impact your portfolio. This strategy is far more consistently reliable than constantly trying to time the market. With this perspective in mind, there are definitely some businesses that have generated tremendous wealth for their long-term shareholders. In fact, here's one stock that over the course of the past 28 years would have turned a $1,000 initial investment into a holding worth more than $1 million. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Becoming one of the world's dominant enterprises Since this company's initial public offering in May 1997, its shares have produced an unbelievable return of 217,000%. Had you been able to allocate $1,000 to this stock when it went public, you'd be staring at a balance of nearly $2.2 million today. The company in question is none other than Amazon (NASDAQ: AMZN). Its journey -- characterized by constant innovation and pushing the envelope -- has been nothing short of spectacular. Amazon started out in the mid-1990s selling books online. While this was a narrow focus, it was a revolutionary idea at the time. The company wanted to stick to a product category that was easy and low-risk to ship, and one that had a massive selection of items for shoppers to choose from. Over time, Amazon evolved to start selling virtually anything under the sun, and it continues to expand its footprint. In December, for example, the business launched a partnership that allows consumers to buy new Hyundai vehicles on its e-commerce site. The entire car-buying process, from arranging financing to scheduling the delivery from a nearby dealer, can be handled on Amazon. The company enticed shoppers to spend more money on its site by pioneering fast, free shipping, and offering it as a perk of its Prime membership program in 2005. Today, it is estimated that there are more than 200 million Prime members across the globe. In 2006, the company began offering Amazon Web Services (AWS) to external customers. Management realized that other businesses might need solutions to scaling IT infrastructure based on changing needs -- the same issue Amazon faced with its e-commerce operation. In 2024, AWS generated $108 billion of revenue and $40 billion of operating income. It is the world's largest cloud-computing infrastructure provider and a major artificial intelligence (AI) platform. Thanks to the tremendous amount of traffic gets these days, as well as the success of the Prime Video streaming platform, Amazon has become an advertising juggernaut. During the first quarter of 2025, it collected $13.9 billion in digital ad revenue. What the future might hold With a market capitalization of $2.3 trillion and trailing-12-month revenue of $650 billion, Amazon has grown into a colossal entity and delivered incredible gains to its long-term shareholders. But it would be unreasonable to expect it to do anything similar in the future -- it's already one of the five largest companies in the world. Growth can't continue at a rapid pace indefinitely, and given Amazon's current scale, there are limited opportunities for it to do things that could move the financial needle. That doesn't necessarily mean Amazon isn't a worthy investment candidate, though. According to Wall Street consensus analyst estimates, its revenue is projected to increase at a compound annual rate of 9.5% between 2024 and 2027. That's certainly an encouraging sign. Even better, its bottom line is soaring thanks to cost cuts and operational efficiencies. Diluted earnings per share (on a split-adjusted basis) went from $3.21 in 2021 -- and a $0.27 loss in 2022 -- to $5.53 in 2024. Those impressive gains make the current valuation reasonable, in my view. As of June 19, the stock trades at a forward price-to-earnings ratio of 34.3. Amazon won't turn a $1,000 investment into $2.2 million over the next 28 years. However, this business should be on every long-term investor's radar. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Style Blueprint
8 hours ago
- Style Blueprint
Meet Deeannah Seymour, Founder of pH-D Feminine Health
Share with your friends! Pinterest LinkedIn Email Flipboard Reddit Deeannah Seymour turned an awkward problem into an entrepreneurial revolution. After discovering boric acid could solve a deeply personal issue, she founded pH-D Feminine Health and launched a quiet uprising in women's wellness. What began with a single product has grown into a movement of education and empowerment. Meet the woman sparking smarter conversations and redefining how we care for our bodies, Deeannah Seymour. Pin What first sparked the idea for pH-D Feminine Health? It's true what they say … necessity is the mother of invention. I had struggled with my own feminine care issues, and I was looking for a holistic solution backed by science. I found it in an ingredient called boric acid, in the form of vaginal suppositories. This ingredient changed my life, and I knew I had to find a way to bring it to market, knowing it would benefit millions of women. Have you found it tricky to start the dialogue about feminine health? Since day one of starting pH-D, we have been intentional about creating a platform where we can have open, honest conversations surrounding feminine health. Our brand was one of the first to openly discuss and educate on two of the top reasons women will visit a doctor: feminine odor and itch. In doing so, we're working to remove the shame and stigma associated with these deeply personal issues that most women experience at some point in their lives. It's been incredible to witness the effects of creating a safe space for these conversations. Women (and men alike) are engaging and tagging each other … all in an effort to lift each other up and help friends or loved ones find solutions for their feminine health issues. We're proud to announce the launch of our boldest initiative yet: Raise Your Vagina iQ™, a nationwide campaign that kicked off with two billboards in Times Square, joined by the always-fabulous Sonja Morgan of The Real Housewives of New York City. This movement was born from a decade of witnessing just how many women struggle to describe what's happening with their own bodies because they were never taught the accurate, anatomical language to do so. Instead, many were encouraged to use vague or 'softer' terms, reinforcing the idea that real words are somehow inappropriate. That language gap has real consequences, especially in medical settings, where too often, women don't receive the care they need simply because they can't clearly express their symptoms. To help bridge that gap, we created a fun, accessible online quiz and educational platform that empowers women (and men!) to better understand and communicate about feminine health. Are you a VagiNewbie, a VaGenius, or maybe even a VaGedictorian? Take the quiz and find out because smarter words lead to smarter care. Pin Women's health has often been misunderstood or ignored. How did you decide where to begin making a difference in such a sensitive space? It's no secret that women's health has historically been underfunded, under-researched, and undervalued — and our story is a powerful example of that. The solution I brought to market, boric acid suppositories, had been used for decades but was only available through expensive, inconvenient compounding pharmacies. Legacy companies overlooked it entirely because there was no intellectual property protection, meaning anyone could replicate the product once it was launched. That didn't stop me. I wasn't motivated by exclusivity; I was driven by purpose. I had experienced firsthand how life-changing this product could be, and I felt a moral obligation to make it accessible to the millions of women who needed it. We didn't expect just how massive the unmet need truly was. By introducing boric acid suppositories into mainstream retail, we didn't just launch a product — we created an entirely new category in the feminine care industry. And that category has given women across the country a safe, effective, affordable alternative they didn't even know was possible. Pin What are some of your most memorable 'pinch-me' moments? Some of my most unforgettable 'pinch-me' moments come from conversations with our customers and the healthcare providers who trust and recommend our products. I've had thousands of deeply moving interactions — many tearful — where women have shared that our products changed their lives, restored their confidence, saved their marriages, or finally gave them relief after years of suffering. Providers have told me we've transformed how they practice medicine and helped them significantly reduce their reliance on antibiotics. There's no greater reward than knowing the work my team and I are doing is truly making a global impact on women's health. Where do you see the conversation around women's wellness heading in the next few years, and what change would you love to see? Over the past two years, we've seen a powerful shift in the conversation around women's health, particularly when it comes to menopause. And it's long overdue. My own mother endured menopause in silence because it simply wasn't talked about. Today, thanks to high-profile women who are openly sharing their experiences, more women feel empowered to speak up, seek care, and finally feel seen. As a result, many are reclaiming their health, energy, and lives. That said, we still have a long way to go, especially when it comes to equitable representation in clinical trials and the development of treatments truly tailored to women. But I believe we're at a tipping point. Women are starting to demand better care for themselves and future generations. And that demand is what will ultimately lead to better outcomes, better innovation, and a dramatically improved quality of life for women everywhere. Pin You spend a lot of time helping others. What do you do to embrace your own self-care? I'm on the road for at least six months of the year. A year ago, with a renewed focus on my health, I joined an all-women's gym called TNB Fitness. When I'm in town, I get up at 5 a.m. so I can be in the gym at 6 a.m. and in the office by 8 a.m. When I'm on the road, I get to the hotel gym or try to move as much as I can. Sometimes, it's a fast-paced walk (or run) through the airport. I also love my pop-up infrared sauna. What's something about you that might surprise people? I am a living organ donor, an experience that forever changed my life. Nearly 11 years ago, I donated a kidney to my friend's four-year-old son, Jake. Saying yes to that decision taught me one of the greatest lessons of my life: how to quiet the noise, listen to where we're being guided, and choose faith over fear. Pin What's the best piece of advice you've ever received? One of the most lasting lessons my dad taught me was simple: 'Whatever is worth doing, is worth doing well.' That quote still sits on my desk today. He reminded us often that no task, no matter how small or routine, was beneath our best effort. Whether it was a major project or a menial chore, doing it well meant doing it with integrity, so it wouldn't have to be redone or regretted. That mindset has stayed with me throughout my life and career. Outside of faith, family, and friends, what three things can't you live without? Bow (our black German Shepherd), Mexican food, and traveling. ********** For more inspiring stories, visit our FACES archives! About the Author Jenna Bratcher Jenna Bratcher is StyleBlueprint Nashville's Associate Editor and Lead Writer. The East Coast native moved to Nashville 17 years ago, by way of Los Angeles. She is a lover of dogs, strong coffee, traveling, and exploring the local restaurant scene bite by bite.
Globe and Mail
11 hours ago
- Globe and Mail
MSTR Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MicroStrategy Incorporated d/b/a Strategy (MSTR) Shareholders of Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - June 21, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') (NASDAQ: MSTR) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategyinvestors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
